Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: OncoSil up 15pc on German device funding; Starpharma expands to Middle East
Health & Biotech
Creso Pharma stakes its claim of the multibillion US CBD market in landmark acquisition
Health & Biotech
Creso Pharma takes cannabis into the metaverse, creating Creso verse on The Sandbox
Health & Biotech
ASX Health Stocks: Cannabis play BOD to start clinical trial of CBD drug for COVID
Health & Biotech
Creso Pharma reveals new CEO, adds serious heavy-hitters to North American ops
Health & Biotech
ASX Health Stocks: Polynovo jumps 18pc with record US sales in December
Health & Biotech
ASX Pot Stocks: MMJ invests $1 million in Weed Me, Creso plans US ImpACTIVE launch
Health & Biotech
Weed Week: Cannabis advent calendars and US Republicans introduce weed bill for veterans
Health & Biotech
Creso Pharma ready to move as Republicans ramp up legal cannabis push in US
Health & Biotech
Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials
Health & Biotech
BluView: Investors bullish on cannabis sector, and its pot stocks worth watching
Health & Biotech
Weed Week: Belushi and Aykroyd get the band back together to promote cannabis
Health & Biotech
ASX Health Stocks: Noxopharm gets initial nod for patent, Rhythm tops 11pc on imminent market launch
Health & Biotech
Creso Pharma makes inroads in North America and enters the sports market for CBD after acquisition
Health & Biotech
Dr Boreham’s Crucible: 4 ASX stocks focused on a mind-altering $25 billion psilocybin market
Health & Biotech
The TGA could soon relax rules on psychedelics. Here are the ASX stocks that could benefit
Health & Biotech